Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party

MLA

Adrian Bloor, et al. “Brentuximab Vedotin for Recurrent Hodgkin Lymphoma after Allogeneic Hematopoietic Stem Cell Transplantation: A Report from the EBMT Lymphoma Working Party.” Cancer, vol. 125, Oct. 2018, pp. 90–98. EBSCOhost, https://doi.org/10.1002/cncr.31755.

APA

Adrian Bloor, Stephen D. Robinson, Peter Dreger, Ram Malladi, Gonzalo Gutierrez Garcia, Silvia Montoto, Albert Esquirol, Hervé Ghesquières, Didier Blaise, Zafer Gulbas, Boris V. Afanasyev, Herve Finel, Karl S. Peggs, Mohamad Mohty, Ariane Boumendil, David Michonneau, Francesca Bonifazi, Jean El-Cheikh, Jeremy Delage, … J. L. Diez-Martin. (2018). Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer, 125, 90–98. https://doi.org/10.1002/cncr.31755

Chicago

Adrian Bloor, Stephen D. Robinson, Peter Dreger, Ram Malladi, Gonzalo Gutierrez Garcia, Silvia Montoto, Albert Esquirol, et al. 2018. “Brentuximab Vedotin for Recurrent Hodgkin Lymphoma after Allogeneic Hematopoietic Stem Cell Transplantation: A Report from the EBMT Lymphoma Working Party.” Cancer 125 (October): 90–98. doi:10.1002/cncr.31755.